Demographics, Latency, and Mortality of Severe Cutaneous Adverse Reactions in an FDA Database

Eric Milan Mukherjee MD PhD[1, 2], Dodie Park[2], Matthew S. Krantz MD[2,3], Cosby A. Stone Jr. MD MPH[2,3],

Michelle Martin-Pozo PhD[2,3], Elizabeth Phillips MD[2,3,4]*

[1]Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

[2]Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

[3]Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville,

Tennessee, USA

[4]Institute for Immunology and Infectious Diseases, Murdoch University, Perth, AustraliaPT

*Corresponding author: elizabeth.j.phillips@vumc.org

Keywords: Severe Cutaneous Adverse Reactions, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug

Reaction with Eosinophilia and Systemic Symptoms, Acute Generalized Exanthematous Pustulosis,

Pharmacovigilance, FAERS.

World Count: 3000

Abstract

Importance: Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS-TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), are rare but potentially fatal. Limited large-scale data exists on their global burden, causative agents, latency, and mortality.

Objective: To characterize the epidemiology, causative agents, drug latency, and mortality of SCARs using a large pharmacovigilance database.

Design: Cross-sectional study of spontaneous adverse event reports. Cases were drawn from the U.S. Food and Drug Administration Adverse Event Reporting System (FDA FAERS) from January 2004 to December 2023 and subjected to sanitization and deduplication. Disproportionality analysis was used to characterize causative agents. Machine learning (random forest classifiers) was used to analyze predictors of drug latency and mortality.

Setting: Global pharmacovigilance reports submitted to FAERS.

Participants: A total of 56,683 deduplicated reports of SCARs were identified, representing 0.33% of all reports during the study period.

Exposures: Suspected causative drugs, including both small molecules and biologics.

Main Outcomes and Measures: Primary measures included drug latency (time from drug exposure to adverse reaction) and mortality. Key covariates included causative drug, age, sex, number of concomitant medications, and geographic region.

Results: SCAR reporting increased over time, particularly for biologics and immune checkpoint inhibitors. Over 200 drugs showed positive disproportionality signals. Co-reporting of multiple SCAR was observed in hundreds of cases, suggesting possible overlap conditions. Latency varied by phenotype (median: GBFDE, 3.3 days; AGEP, 4.2 days; SJS-TEN, 11.8 days; DRESS, 19.8 days) and was most influenced by causative drug and number of concomitant medications. Mortality differed by phenotype (SJS-TEN, 22.8%; AGEP, 3.1%; DRESS, 5.7%; GBFDE, 20.0%) and increased with age and polypharmacy. Random forest classifiers identified drug identity, age, and number of medications as the strongest predictors of latency and mortality.

Conclusions and Relevance: This large-scale analysis highlights evolving patterns in SCAR epidemiology and identifies key clinical predictors of latency and mortality. These findings underscore the utility of pharmacovigilance

56   databases and machine learning in studying rare cutaneous drug reactions and may aid in earlier recognition and risk

57   stratification.

Introduction

Adverse drug reactions (ADR) are one of the top 10 causes of death in the developed world, costing up to $130 billion annually in the US.[1] Among the most serious ADRs are severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS-TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and generalized bullous fixed drug eruption (GBFDE). These conditions are distinguished by morphology, causative agents, systemic involvement, and latency. For instance, AGEP and GBFDE manifests within hours to days of exposure, while DRESS and SJS-TEN can take weeks.[2]

SCAR has incidence of 0.4 to 0.6 per million/year in the developed world, with mortality up to 70 percent in high-risk populations.[2] SCAR can lead to signficant skin damage, systemic involvement, and long-term sequelae. Because of their rarity, SCAR are difficult to study at scale. The largest published retrospective studies of SCAR have 300-400 cases; the largest meta-analysis of SJS-TEN had 2917 patients.[3,4] Thus, there are many unanswered questions, including intermediate phenotypes between different SCAR, variations in mortality and phenotype between causative agents, and geographic and temporal variation.

The FDA Adverse Event Reporting System (FAERS) is a valuable public database collecting information on ADRs. FAERS contains millions of reports submitted by providers, patients, and manufacturers. However, FAERS is hampered by unstructured drug names, duplication, and inconsistent detail.[5] In this study, we sanitized FAERS and analyzed SCAR reports from 2004 to 2023, focusing on temporal trends, disproportionality, and overlap conditions. With this largest real-world retrospective dataset of SCAR to date, we could also analyze drug latency and mortality using machine learning (ML) techniques, gaining key insights.

Methods

Coding was done in RStudio 2024.12.0 Build 467 with R version 4.4.2, Pycharm 2024.2.0.1 with Python 3.12, PostgreSQL 16.3 (with PgAdmin IV), with GPT4o assistance. Further details available in **Online Supplement 1**.

Data

Preparation is summarized in **eFigure 1**. Quarterly ASCII files were fed into AEOLUS, which maps drugs and outcomes to standardized vocabularies and deduplicates by removing cases that match all four demographic fields

(event date, age, sex and reporter country).[6] Unmapped drugs and outcomes were manually mapped by two

researchers (EMM and DP), resulting in 100% mapping of rows in both tables.

Time-to-Event Analysis and Random Survival Forests

After filtering and outlier removal, 13633 SCAR cases had sufficient data for TTE analysis. Random survival forests

(RSFs) are a method of analyzing TTE based on random forest (RF) classifiers. Like RFs, RSFs are bootstrapped

aggregates of hundreds of decision trees, well-suited for analyzing high-dimensional data with interacting, nonlinear

variables.[7] We generated RSFs for each SCAR and for all SCAR aggregated using the Python package scikit-

survival (version 0.23.1), after a grid search for hyperparameter optimization. The covariates were causative drug,

sex, region, age, number of concomitant drugs, and indicator for each SCAR (SJS-TEN, DRESS, AGEP, GBFDE)

when applicable. Variable importance (VIMP) for each covariate was determined by bootstrapping. Model fit was

assessed using the concordance index (C-index). Survival curves were generated for stratified covariates.

Mortality

13540 SCAR cases had both TTE and mortality information. RFs were trained on all cases using age, sex, region,

causative drug, TTE, and Boolean variables for each SCAR as covariates. Due to technical limitations, the top 50

causative drugs were included, and the rest coded as "other". Separate RFs were trained for SJS-TEN, DRESS, and

AGEP, using the same demographic covariates. All RFs were created after hyperparameter tuning by grid search and

trained using five-fold cross-validation.

Results

Demographics

A total of 56,683 SCAR cases were identified, comprising 0.33% of total reports during this period. The most

frequently reported was SJS-TEN (28,871), then DRESS (22,444), AGEP (6,183), and GBFDE (150). The number

of reports over time, age, gender, and geographic distribution are summarized in **Figure 1**. Reports increased from

2004-2023, peaking in 2019. While the number of new SJS-TEN cases have stayed relatively flat, new DRESS

cases have steadily increased, overtaking new SJS-TEN cases in 2017.

Age statistically differs between SCAR, with GBFDE having lowest median (46 years, IQR [35-65]), then

SJS-TEN (52 years, [30-68]), DRESS (52 years, [31-66]), and AGEP (59 years, [41-73]). Each SCAR shows female

predominance except GBFDE. Analyzing sex and age (**eFigure 2**) shows that males have a bimodal age distribution,

while female patients overtake males in adolescence before "catching up" in older age. Reports originate from 140

countries and territories (**eFigure 3**). USA (15607), France (9530), and Japan (5248) contributed the most reports.

SJS-TEN outnumbers DRESS in all top 10 countries except for France, Spain, and Portugal. India reports the most

GBFDE (44 cases), followed by France (28), the US (15) and Iran (15).

Temporal Trends in Causative Agents

Using criteria from Evans et al (>2 cases, PRR ≥ 2, chi-squared ≥ 4), we find 237 drugs with positive signal when

aggregating all SCAR together (**Online Supplement 2**).[8] When splitting by phenotype, there were 229 drugs with a

positive signal for SJS-TEN, 161 for DRESS, 130 for AGEP, and 16 for GBFDE.

We analyzed temporal trends in SCAR reporting (**Figure 2**). The top five causative agents (allopurinol,

vancomycin, lamotrigine, ibuprofen, and carbamazepine) are consistently responsible for ~20% of new reports. The

proportion of new reports due to biologics has steadily increased over time (p < 0.0001 by the Cochrane-Armitage

test), comprising 8.2% of new reports in 2023, up from 2.6% in 2015 and 1.2% in 2004. Subdividing biologics by

function, cases associated with ICIs have increased steadily since their 2011 approval (p < 0.0001, Cochrane-

Armitage), comprising 49.1% of reports with a biologic as the primary suspect in 2023.

Disproportionality Analysis

Figure 3 plots the information content (IC) of the top ≤20 drugs with >2 cases. **eFigure 4** shows the top 100 drugs

when aggregating all SCAR together. Several well-known culprits (e.g. lamotrigine, allopurinol, and phenytoin for

SJS-TEN, allopurinol, vancomycin, and lamotrigine for DRESS) are strongly associated (IC ≥ 3). Other, less-well-

known associations (e.g., enfortumab and zonisamide for SJS-TEN, ciprofloxacin and valacyclovir for DRESS)

have clear positive signals.[9–11]

Interestingly, some suspects have negative IC (**eFigure 5**), meaning they are less frequently associated with

SCAR than expected. Many of these (lenalidomide, adalimumab, etanercept, and ocrelizumab) are

immunomodulators infrequently (and controversially) implicated in SCAR in individual cases.[12–14] Some hormonal

medications (testosterone, levonorgestrel), psychiatric medications (methylphenidate, aripiprazole), and anti-

osteoporotic agents (denosumab, zoledronic acid) also have negative IC.

Disproportionate Co-Reporting

Overlap conditions between SCAR are rare and difficult to diagnose.[15] Disproportionality of co-occurring SCAR is

shown in **eFigure 6**. For SJS-TEN/DRESS, allopurinol (71 cases), lamotrigine (71), and phenytoin (49) are the most

frequent suspects and have IC > 3. Co-reporting with AGEP is rarer; phenytoin (26 cases), ciprofloxacin (18), and

allopurinol (14) are the most frequent culprits with co-reported DRESS, all with IC > 3, and phenytoin (34 cases),

amlodipine (29), and ibuprofen (13) are the most frequent suspects of co-reported SJS-TEN. We analyzed cases

reporting more than one SCAR, and included other generalized cutaneous ADR (pemphigus, pemphigoid, SDRIFE,

FDE, LABD, and systemic contact dermatitis), which can be confused with SCAR (**eFigure 7**). A binomial model

assessed whether co-reporting was more frequent than expected by random co-occurrence. There were 231 cases of

SJS-TEN/AGEP (p = 2.37e-206), 576 of SJS-TEN/DRESS (p < 1e-207), and 205 of AGEP/DRESS (p = 3.5e-194).

Co-reporting between SCAR and non-SCAR is less pronounced, with the most significant occurring between SJS-

TEN and LABD (43 cases, p = 9.65e-41), and SJS-TEN and pemphigoid (63 cases, p = 1.45e-28). Pemphigoid and

LABD, bullous conditions that can mimic, had 14 co-reporting cases (p = 1.29e-15), and pemphigus and

pemphigoid had 44 (p = 2.18e-35).

Latency Varies by Causative Drug and SCAR

We conducted TTE analysis on a subset of cases (n = 13,633, **Figure 4A**). Latency differed by phenotype (p <

0.0001 by log-rank), with GBFDE having the shortest (3 days, IQR [2-3], n = 5), followed by AGEP (4d, [2-9], n =

1541), SJS-TEN (12d, [6-23], n = 7230), and DRESS (20d, [9-31], n = 5021). Median latency varies by causative

drug (**Figure 4B**). For SJS-TEN, NSAIDs (ibuprofen, acetaminophen) and antibiotics (ceftriaxone, amoxicillin,

azithromycin) have short latency, while ICI (pembrolizumab, nivolumab), allopurinol, and some anticonvulsants

(zonisamide and phenytoin) have long latency. For DRESS, ibuprofen, amoxicillin, and the kinase inhibitor

vemurafenib have short latencies, while the protease inhibitor telaprevir has a median latency of 42 days. For AGEP,

a few drugs have long latency (vancomycin, hydroxychloroquine, terbinafine).

RSFs were constructed using SCAR phenotype, age, sex, region, causative drug, and number of

concomitant drugs as covariates. The resulting RSF had C-index 0.7791 (**eFigure 8**). When considering TTE by

phenotype from this RSF (thus controlling for all other variables), we found DRESS has the longest median latency

(19.84 days, IQR [8.96, 30.95]), followed by SJS-TEN (11.82d, [5.77, 22.91], AGEP (4.19d, [1.87, 8.96]), and

GBFDE (3.28d, [1.94, 6.37]). Variable Importance (VIMP) for each covariate showed that causative drug had the

largest influence, followed by age and number of concomitant medications. To better characterize latency within

each phenotype, we created separate RSFs for each, with C-indices 0.7953, 0.7977, and 0.7668 for SJS-TEN,

DRESS, and AGEP. VIMPs showed that causative agent had the largest influence, followed by age and concomitant

medications (**eFigure 9**).

We additionally calculated survival curves stratified by each covariate (**eFigure 10**). For all SCAR

combined, the log-rank test conducted on each covariate (age, sex, region, and number of concomitant drugs)

suggests significant differences. For SJS-TEN and DRESS, however, only region and age are significant (p <0.001),

while for AGEP only region is significant (p = 0.0229). For all SCAR, SJS-TEN, and DRESS, the 0–20-year and

80–100-year age group had shortest latency. There is significant regional variation in latency, with the regions

showing shortest and longest latency differing by SCAR phenotype.

Mortality

For 13540 cases with sufficient data, mortality was computed by age, concomitant drug count, TTE, sex, region, and

phenotype (**eFigure 11**). Mortality rises with age and number of concomitant drugs, reaching 34.58% for cases with

at least 12 drugs. Similar trends characterize individual SCAR (**eFigure 8-10**). SJS-TEN has the highest mortality

(22.8%), followed by GBFDE (20%), DRESS (5.66%) and AGEP (3.13%). Regionally, North America has the

lowest mortality (8.61%) and Sub-Saharan Africa has the highest (24.0%).

RFs were used to determine the influence of each variable on the mortality rate, and partial dependence

plots (PDPs) were created to assess the influence of a single covariate while averaging the others (**Figure 5**).

Predicted mortality still increased with age and number of concomitant drugs, though with a marked increase for

patients <5 years old. Predicted female mortality rate remained slightly lower than the male rate. When considering

mortality per SCAR, SJS-TEN is markedly higher than the others, followed by GBFDE, DRESS, and AGEP. VIMPs

showed age and concomitant count were the most influential, though the binary SJS-TEN variable had highest

VIMP overall. Subsequently, we constructed separate RFs on SJS-TEN, DRESS, and AGEP cases (**eFigure 15-17**,

respectively). Individual SCAR showed increased mortality with age and concomitant drug count. VIMPs from each

of these RF similarly show age and concomitant count have the most influence on predicted morality, with TTE and

causative drug also having significant importance.

Discussion

We report a comprehensive cross-sectional analysis of 56,683 SCAR cases from FAERS, 10-100x more than

previous studies. Reported causative agents include well-known culprits like beta-lactams, anticonvulsants, and

allopurinol, and less-studied agents like immunomodulators. The FDA's Drug Safety-related Labeling Changes

(SrLC) lists nine drugs since 2016 with label changes due to a link with SJS-TEN and/or DRESS – lamotrigine,

allopurinol, phenytoin, carbamazepine, amoxicillin, trimethoprim-sulfamethoxazole (TMP-SMX), rifampin,

levetiracetam, and vancomycin.[16] Importantly, four of these drugs with the most label changes since 2016 for

SCAR, DRESS, and/or SJS-TEN (allopurinol – 4 changes, phenytoin – 6 changes, rifampin – 5 changes, and TMP-

SMX – 4 changes), are the same drugs that we found to be disproportionately represented in our data, providing

evidence of the robustness of our methods but also indicating that these label changes may have impacted reporting.

The impact of these findings is underscored by the methods used to prepare FAERS, and by the breadth of

medications studied. Prior studies have been limited by smaller sample sizes or focus on a few drugs.[17,18]

Additionally, prior studies have not been as thorough in sanitization, including limited deduplication efforts and lack

of stringency in drug naming. The issue of deduplication is well-documented in the literature, and is an area of

active improvement.[5,19] Even with our efforts, clear limitations remain. FAERS relies on voluntary reporting and has

unclear reporting requirements for any given condition (e.g. DRESS or AGEP meeting RegiSCAR or EuroSCAR

criteria), leading to potential reporting biases. Detail varies by case, with some omitting concomitant drugs, exact

dates, and phenotyping. Furthermore, it is likely that duplicated entries and typographical errors remained, and more

advanced methods based on natural language processing and probabilistic grouping can address these

shortcomings.[20–22] Future studies should continue to improve on these methods using more advanced techniques.

The Changing Landscape of SCAR

SCAR reporting in FAERS has increased over time. For DRESS, this is likely due to the condition first being named

in 1996, criteria being published in the mid-2000s, and FAERS first reporting in 2003.[23] GBFDE, known since the

1980s, has only been reported in FAERS since 2021.[24] While the plurality of reports are from high-resource nations,

there are many reports from middle- and lower-income nations, reflecting SCAR's global nature.

Particularly striking is the fact that ICIs are on the rise as a cause. ICI-induced SCAR presents a

mechanistic challenge. While small molecules cause SCAR by perturbing the TCR-peptide-MHC complex, ICIs

likely exert their influence through inhibiting tolerance, leading to organ toxicities including SJS-TEN-like

reactions.[25] ICIs have a longer latency than other medications in our data, corroborating that they may have a

different pathomechanism. Furthermore, ICI-induced SCAR may be truly ICI-induced, or ICIs may facilitate small-

molecule-induced SCAR via their mechanism. Further studies of this population, with precise clinical data, are

needed.

Overlap Conditions

Full phenotyping and histopathology are often required to diagnose conditions meeting the criteria of >1 SCAR.

While such data is unavailable in FAERS, our work offers some insights. We demonstrate that co-reporting is higher

than expected by random assortment and occurs more frequently than with other cutaneous conditions commonly

misdiagnosed for each other (e.g. autoimmune bullous disease).

SJS-TEN/DRESS overlap, meaning cases meeting criteria for both diseases, has been reported with

allopurinol, anticonvulsants and TMP-SMX, among others.[26,27] AGEP/DRESS overlap is more difficult – the

condition is recognized as a discrete entity within FAERS; in our data it appears in one case (primary suspect

levofloxacin). Pustular DRESS is a known phenotype, with vancomycin, phenytoin, doxycycline and piperacillin-

tazobactam implicated in a recent review (noting that these patients didn't meet full AGEP criteria).[28] A retrospective

study of 216 patients found one probable case of DRESS-AGEP overlap meeting both criteria.[29] Similarly, AGEP

with TEN-like features, or AGEP/SJS-TEN overlap, is increasingly recognized.[30] Many present with widespread

desquamation and mucosal involvement that appears SJS-TEN-like, but with pathology showing pustules. Because

histopathology is needed, many cases of both true AGEP/SJS-TEN overlap and AGEP with SJS-TEN-like features

are likely misdiagnosed. Further harmonization of criteria and coordination are needed to characterize these cases.

Causative Agents and Latency

Drug latency is critical in the management of SCAR; in tandem with drug timelines, prior knowledge of latency is

vital to determining the causative agent in complex cases. We have demonstrated that the causative agent is the

strongest influence on latency, and that some agents have unusually long or short latencies, which is valuable

knowledge in a clinical setting. The reason for the dependence of latency on causative agent is not well-understood

and bears further study, perhaps by considering chemical structure, metabolism, and time needed for antigen

presentation.

A controversy in the field of SCAR is protopathic bias – namely, when a drug is misattributed as causative

because it is prescribed early during SCAR to another drug. This is particularly notable for NSAIDs, which are often

prescribed in the flu-like prodromal phase of SJS-TEN, and which have low latency (4-5 days) in our data. An

internal FDA review suggested acetaminophen caused rash, and mucosal erosion with a 1-3 day delay.[31] Some

antibiotics like amoxicillin and azithromycin may be protopathic due to being prescribed for subjective malaise. A

concerted effort to confirm these cases with follow-up testing would be helpful.

Insights from Machine Learning

For the first time, we applied random forests to SCAR pharmacovigilance. These methods are particularly suited for

complex data with interdependent variables – particularly relevant to SCAR, in which age, causative agent, sex, and

number of concomitant drugs likely interact. While previous studies have applied ML to pharmacovigilance, none

have used it to predict TTE or mortality, and none have applied them to SCAR.[32,33] Using RSFs, we have shown that

age, sex, region, and number of concomitant drugs have an influence on latency. Interestingly, younger patients had

shorter latency, even when controlling for other variables (including the causative drug), likely due to faster antigen

processing or metabolism. There is also regional variation in latency, which may arise from differences in diagnosis

and surveillance. A larger dataset, with clear criteria for SCAR, well-defined TTE data, and causative agent

determination, is likely required to gain insights into the role of demographic variables in latency. Such information

would be clinically valuable, particularly for difficult cases in which the causative drug is hard to determine.

Rare events like SCAR are ideal subjects of study using large pharmacovigilance databases like FAERS,

which aggregate data worldwide to provide large datasets amenable to deeper analyses. However, these databases

suffer from issues with duplication, missing data, and reporting bias. As a rare disease, SCAR is particularly

complicated to study, with phenotypic variation, misdiagnosis, inconsistent criteria, genetic influences, and difficulty

determining the causative drug. We hope that our study, and the application of more advanced deduplication and

analysis techniques, will spur new insights into SCAR.

Data Sharing

Methods and data are available at https://github.com/capuhcheeno/SCARs_ICI-Manuscript-Scripts.

Contributions

EMM conceived the project, wrote the manuscript, and conducted all analyses. DP conducted analysis and edited the

manuscript. MMP, MSK, and CAS assisted with analysis and reviewed the manuscript. EP reviewed all analyses and

the manuscript.

Acknowledgements

E.J.P. is supported by the following grants from the National Institutes of Health (NIH): NIH U01AI154659, NIH

P50GM115305, NIH R01HG010863, NIH R21AI139021, NIH R01AI152183, and NIH 2 D43 TW010559. E.J.P. is

also supported by the National Health and Medical Research Council of Australia. E.M.M. is funded by a Vanderbilt

University Medical Center internal career development award (Vanderbilt Faculty Research Scholars).

Conflict of Interest

E.J.P. receives royalties and consulting fees from UpToDate and Uptodate Lexidrug (where she is a Drug Allergy

Section Editor and section author) and has received consulting fees from Janssen, Vertex, Verve, Servier, Rapt and

Esperion. E.J.P. is co-director of IIID Pty Ltd, which holds a patent for HLA-B*57:01 testing for abacavir

hypersensitivity, and E.J.P has a patent pending for detection of HLA-A*32:01 in connection with diagnosing drug

reaction with eosinophilia and systemic symptoms to vancomycin. For these patents she does not receive any

financial remuneration, and neither are related to the submitted work.

Statement on Use of Artificial Intelligence

GPT4o was used to write, optimize, and debug R, SQL and Python code. Suggestions were cross-referenced in

literature, package documentation, and resources like stackoverflow.com. All code and generated data were

manually reviewed, tested, and verified by the authors. The authors take responsibility for all code generated.

309
310

References

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized
patients: a meta-analysis of prospective studies. *JAMA*. 1998;279(15):1200-1205.
doi:10.1001/jama.279.15.1200

2. Hung SI, Mockenhaupt M, Blumenthal KG, et al. Severe cutaneous adverse reactions. *Nat*
Rev Dis Primers. 2024;10(1):1-25. doi:10.1038/s41572-024-00514-0

3. Creadore A, Desai S, Alloo A, et al. Clinical Characteristics, Disease Course, and Outcomes
of Patients With Acute Generalized Exanthematous Pustulosis in the US. *JAMA*
Dermatology. 2022;158(2):176-183. doi:10.1001/jamadermatol.2021.5390

4. Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens-Johnson Syndrome/Toxic
Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the
United States. *J Invest Dermatol*. 2018;138(11):2315-2321. doi:10.1016/j.jid.2018.04.027

5. Giunchi V, Fusaroli M, Hauben M, Raschi E, Poluzzi E. Challenges and Opportunities in
Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach. *Drug Saf*.
2023;46(10):921-926. doi:10.1007/s40264-023-01345-w

6. Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and
standardized adverse drug event resource to accelerate drug safety research. *Sci Data*.
2016;3:160026. doi:10.1038/sdata.2016.26

7. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. *Ann Appl*
Stat. 2008;2(3). doi:10.1214/08-AOAS169

8. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal
generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol Drug Saf*.
2001;10(6):483-486. doi:10.1002/pds.677

9. Nguyen MN, Reyes M, Jones SC. Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. *JAMA Dermatology*. 2021;157(10):1237-1239. doi:10.1001/jamadermatol.2021.3450

10. Vivar KL, Mancl K, Seminario-Vidal L. Stevens–Johnson syndrome/toxic epidermal necrolysis associated with zonisamide. *Clin Case Rep*. 2017;6(2):258-261. doi:10.1002/ccr3.1288

11. Alkhateeb H, Said S, Cooper CJ, Gaur S, Porres-Aguilar M. DRESS syndrome following ciprofloxacin exposure: An unusual association. *Am J Case Rep*. 2013;14:526-528. doi:10.12659/AJCR.889703

12. Allegra A, Alonci A, Penna G, et al. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. *Hematol Oncol*. 2012;30(1):41-45. doi:10.1002/hon.1000

13. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. *World J Gastroenterol*. 2009;15(35):4449-4452. doi:10.3748/wjg.15.4449

14. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. *Ann Oncol*. 2002;13(12):1948-1950. doi:10.1093/annonc/mdf350

15. Horcajada-Reales C, Pulido-Pérez A, Suárez-Fernández R. Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist? *Actas Dermo-Sifiliográficas (English Edition)*. 2016;107(1):23-33. doi:10.1016/j.adengl.2015.11.003

16. Drug Safety-related Labeling Changes (SrLC). Accessed February 26, 2025. https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/

17. Zhou L, Yang J, Xiao M, et al. Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system events. *Expert Opinion on Drug Safety*. 0(0):1-8. doi:10.1080/14740338.2023.2278685

18. Mao K, Li J, Zhu X, Sun H, Zhong S, Mao W. Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database. *Expert Rev Clin Pharmacol*. 2024;17(1):101-110. doi:10.1080/17512433.2023.2294002

19. Kiguba R, Isabirye G, Mayengo J, et al. Navigating duplication in pharmacovigilance databases: a scoping review. *BMJ Open*. 2024;14(4):e081990. doi:10.1136/bmjopen-2023-081990

20. Artificial Intelligence-based Deduplication Algoirthm for Classfication of Duplicate Reports in the FDA Adverse Event Reports (FAERS) | ACT-IAC. Accessed May 7, 2025. https://www.actiac.org/et-use-case/artificial-intelligence-based-deduplication-algoirthm-classfication-duplicate-reports

21. Kreimeyer K, Spiker J, Dang O, De S, Ball R, Botsis T. Deduplicating the FDA adverse event reporting system with a novel application of network-based grouping. *J Biomed Inform*. 2025;165:104824. doi:10.1016/j.jbi.2025.104824

22. Kreimeyer K, Dang O, Spiker J, et al. Increased Confidence in Deduplication of Drug Safety Reports with Natural Language Processing of Narratives at the US Food and Drug Administration. *Front Drug Saf Regul*. 2022;2. doi:10.3389/fdsfr.2022.918897

23. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. *Br J Dermatol*. 2007;156(5):1083-1084. doi:10.1111/j.1365-2133.2007.07807.x

24. Kauppinen K, Stubb S. Fixed eruptions: causative drugs and challenge tests. *Br J Dermatol*. 1985;112(5):575-578. doi:10.1111/j.1365-2133.1985.tb15266.x

25. Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. *J Am Acad Dermatol*. 2020;83(5):1475-1477. doi:10.1016/j.jaad.2020.03.029

26. Van Nguyen K, Van Vu Q, Tran MH, et al. Overlapping Stevens-Johnson Syndrome and DRESS Syndrome Caused by Phenobarbital: A Vietnamese Case Report. *Glob Pediatr Health*. 2023;10:2333794X231216556. doi:10.1177/2333794X231216556

27. Chin LD, MacGillivary ML, Purdy KS, Kirshen C. Stevens-Johnson syndrome with overlapping features of DRESS syndrome: A report of two cases. *SAGE Open Medical Case Reports*. 2024;12:2050313X241307097. doi:10.1177/2050313X241307097

28. Hansen E, Kirven RM, Gallardo M, et al. Drug Reaction With Eosinophilia and Systemic Symptoms With Pustulosis. *JAMA Dermatology*. 2024;160(7):777-779. doi:10.1001/jamadermatol.2024.1082

29. Bouvresse S, Valeyrie-Allanore L, Ortonne N, et al. Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist? *Orphanet Journal of Rare Diseases*. 2012;7(1):72. doi:10.1186/1750-1172-7-72

30. Chowdhury TA, Talib KA, Patricia J, Nye KD, Moosa SA. Rare and Complicated Overlap of Stevens-Johnson Syndrome and Acute Generalized Exanthematous Pustulosis. *Cureus*. 2021;13(6):e15921. doi:10.7759/cureus.15921

31. Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use | FDA. Accessed February 8, 2025. https://dps.fda.gov/omuf/ordersearch/order_otc000035

32. Zhao Y, Yu Y, Wang H, et al. Machine Learning in Causal Inference: Application in Pharmacovigilance. *Drug Saf*. 2022;45(5):459-476. doi:10.1007/s40264-022-01155-6

407 33. Farnoush A, Sedighi-Maman Z, Rasoolian B, Heath JJ, Fallah B. Prediction of adverse drug
408   reactions using demographic and non-clinical drug characteristics in FAERS data. *Sci Rep*.
409   2024;14(1):23636. doi:10.1038/s41598-024-74505-2

Figure Legends

Figure 1. Demographic Summary of SCAR. (A) SCAR reporting over time in FAERS, by quarter. (B) Age

distribution by SCAR. Pairwise comparisons done by Wilcoxon signed-rank test. **$p < 0.01$, ***$p < 0.001$, ****$p <$

0.0001. (C) Sex Distribution by SCAR. All patients without "M" or "F" sex markers were classified as "other". (D)

Top 10 Countries by SCAR cases. Number of cases were aggregated over entire time period (2004 to 2023). US -

United States, FR - France, JP - Japan, GB - Great Britain, ES - Spain, IT - Italy, DE - Germany, CA - Canada, IN -

India, PT - Portugal.

Figure 2. Trends in SCAR Reporting. Number of reports were aggregated by approximately-equal-frequency bins.

(A) Number of SCAR reports whose primary cause is a "top 5" small molecule (allopurinol, carbamazepine,

ibuprofen, lamotrigine, vancomycin), another small molecule, or a biologic. (B) Number of SCAR reports

subdivided by type of biologic. ICI = immune checkpoint inhibitor. (C) Proportion of SCAR reports by drug

category over time. Proportion of biologics has increased over time ($p < 0.0001$ by Cochrane-Armitage test). (D)

Proportion of total biologic-related SCAR reports subdivided by type. Proportion of ICI has increased over time ($p <$

0.0001 by Cochrane-Armitage test).

Figure 3. Disproportionality Analysis. Top <20 drugs for each SCAR by number of cases (with a minimum of 3

cases) are displayed. Each point represents the IC of a given drug-SCAR combination, with the total number of

436 cases noted just above. Confidence intervals span IC025 to IC975. Red dashed line represents IC of 3, suggesting

437 strong disproportionality.

439 **Figure 4. Drug Latency.** (A) Survival curves show clear variation in median TTE/latency per SCAR. P-value by

440 log-rank test. (B) Drug latency varies by causative drug, within each SCAR. The top 40 drugs (by number of cases)

441 were plotted for each SCAR (GBFDE was excluded due to low number of cases). Each point represents median

442 latency for that drug-SCAR combination, with IQR around the median. The "All Drugs" row for each SCAR shows

443 the mean latency for each SCAR for all drugs (including those not displayed).

445 **Figure 5. Partial Dependence Plots (PDP), Variable Importance (VIMP), and Model Performance for**

446 **Random Forest Classifier of SCAR Mortality.** Marginal dependence of mortality on (A) age, (B) sex, (C) number

447 of concomitant medications administered, (D) geographic region, (E) TTE/latency, and (F) SCAR type is obtained

448 from the RF trained on all SCAR cases. (G) VIMP was calculated using 100 bootstrapped samples. Any VIMP over

449 zero contributed to the predictive ability of the RF. GBFDE only had five cases total but was included for

450 completeness. Model performance metrics are also included. OOB - out-of-bag. AUC - area under the curve.

Figure 1. Demographic Summary of SCAR. (A) SCAR reporting over time in FAERS, by quarter. (B) Age distribution by SCAR. Pairwise comparisons done by Wilcoxon signed-rank test. **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) Sex Distribution by SCAR. All patients without "M" or "F" sex markers were classified as "other". (D) Top 10 Countries by SCAR cases. Number of cases were aggregated over entire time period (2004 to 2023). US - United States, FR - France, JP - Japan, GB - Great Britain, ES - Spain, IT - Italy, DE - Germany, CA - Canada, IN - India, PT - Portugal

Figure 2. Trends in SCAR Reporting. Number of reports were aggregated by approximately-equal-frequency bins. (A) Number of SCAR reports whose primary cause is a "top 5" small molecule (allopurinol, carbamazepine, ibuprofen, lamotrigine, vancomycin), another small molecule, or a biologic. (B) Number of SCAR reports subdivided by type of biologic. ICI = immune checkpoint inhibitor. (C) Proportion of SCAR report by drug category over time. Proportion of biologics has increased over time ($p < 0.0001$ by Cochrane-Armitage test). (D) Proportion of total biologic-related SCAR reports subdivided by type. Proportion of ICI has increased over time ($p < 0.0001$ by Cochrane-Armitage test)

Figure 3. Disproportionality Analysis. Top ≤20 drugs for each SCAR by number of cases (with a minimum of 3 cases) are displayed. Each point represents the IC of a given drug-SCAR combination, with the total number of cases noted just above. Confidence intervals span IC025 to IC975. Red dashed line represents IC of 3, suggesting strong disproportionality.

Figure 4. Drug Latency. (A) Survival curves show clear variation in median TTE/latency per SCAR. P-value by log-rank test. (B) Drug latency varies by causative drug, within each SCAR. The top 40 drugs (by number of cases) were plotted for each SCAR (GBFDE was excluded due to low number of cases). Each point represents median latency for that drug-SCAR combination, with IQR around the median. The "All Drugs" row for each SCAR shows the mean latency for each SCAR for all drugs (including those not displayed).

Figure 5. Partial Dependence Plots (PDP), Variable Importance (VIMP), and Model Performance for Random Forest Classifer of SCAR Mortality. Marginal dependence of mortality on (A) age, (B) sex, (C) number of concomitant meds administered, (D) geographic region, (E) TTE/latency, and (F) SCAR type is obtained from the RF trained on all SCAR cases. (G) VIMP was calculated using 100 boostrapped samples. Any VIMP over zero contributed to the predictive ability of the RF. GBFDE only had five cases total, but was included for completion. Model performance metrics are also included. OOB - out-of-bag. AUC - area under the curve.